Drug firm Zydus Cadila today said it has received US health regulator's nod for marketing Tamsulosin capsules, used for treating problems related to urology, in the US.
Zydus Cadila has received an an approval from the US Food and Drug Administration to market Tamsulosin capsules in 0.4 mg strength, the company said in a filing to Bombay Stock Exchange (BSE).
Tamsulosin falls in the urology segment and is indicated for the treatment of Benign Prostatic Hyperplasia and the drug has reported an estimated sales of $2.79 billion in the US in 2009.
Following this approval, the group has now approvals for 54 products for the US market and has so far filed 106 abbreviated new drug application since the commencement of filing process in the 2003-04 fiscal.